Loading clinical trials...
Loading clinical trials...
Diagnosis of Lymphohistiocytic Hemophagocytosis in Intensive Care: Relevance of the Hscore and Search for the Best Diagnostic Markers
Patients with hepatocellular insufficiency and/or cirrhosis are at risk of developing invasive fungal infections, particularly in critical care settings. In international recommendations, voriconazole is positioned as the first-line treatment for invasive aspergillosis. However, this molecule-and the azole class of antifungals-is associated with frequent hepatic toxicity. Available since 2018, isavuconazole appears to be better tolerated in patients without pre-existing liver dysfunction. The aim of this study is to retrospectively evaluate the validity of the hscore in intensive care and resuscitation patients.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
No
Médecine intensive - Réanimation - CHU de Strasbourg - France
Strasbourg, France
Start Date
August 29, 2025
Primary Completion Date
August 1, 2026
Completion Date
August 29, 2026
Last Updated
January 15, 2026
100
ESTIMATED participants
Lead Sponsor
University Hospital, Strasbourg, France
NCT05982769
NCT03208868
NCT07122700
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions